Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Discovery of novel N-hydroxy-2-arylisoindoline-4-carboxamides as potent and selective inhibitors of HDAC11.

Martin MW, Lee JY, Lancia DR Jr, Ng PY, Han B, Thomason JR, Lynes MS, Marshall CG, Conti C, Collis A, Morales MA, Doshi K, Rudnitskaya A, Yao L, Zheng X.

Bioorg Med Chem Lett. 2018 Jul 1;28(12):2143-2147. doi: 10.1016/j.bmcl.2018.05.021. Epub 2018 May 9.

PMID:
29776742
2.

Molecular basis of USP7 inhibition by selective small-molecule inhibitors.

Turnbull AP, Ioannidis S, Krajewski WW, Pinto-Fernandez A, Heride C, Martin ACL, Tonkin LM, Townsend EC, Buker SM, Lancia DR, Caravella JA, Toms AV, Charlton TM, Lahdenranta J, Wilker E, Follows BC, Evans NJ, Stead L, Alli C, Zarayskiy VV, Talbot AC, Buckmelter AJ, Wang M, McKinnon CL, Saab F, McGouran JF, Century H, Gersch M, Pittman MS, Marshall CG, Raynham TM, Simcox M, Stewart LMD, McLoughlin SB, Escobedo JA, Bair KW, Dinsmore CJ, Hammonds TR, Kim S, Urbé S, Clague MJ, Kessler BM, Komander D.

Nature. 2017 Oct 26;550(7677):481-486. doi: 10.1038/nature24451. Epub 2017 Oct 18.

3.

Thiophene carboxamide inhibitors of JAK2 as potential treatments for myleoproliferative neoplasms.

Haidle AM, Zabierek AA, Childers KK, Rosenstein C, Mathur A, Altman MD, Chan G, Xu L, Bachman E, Mo JR, Bouthillette M, Rush T, Tempest P, Marshall CG, Young JR.

Bioorg Med Chem Lett. 2014 Apr 15;24(8):1968-73. doi: 10.1016/j.bmcl.2014.02.064. Epub 2014 Mar 4.

PMID:
24666646
4.

The discovery of reverse tricyclic pyridone JAK2 inhibitors. Part 2: lead optimization.

Siu T, Kumarasinghe SE, Altman MD, Katcher M, Northrup A, White C, Rosenstein C, Mathur A, Xu L, Chan G, Bachman E, Bouthillette M, Dinsmore CJ, Marshall CG, Young JR.

Bioorg Med Chem Lett. 2014 Mar 15;24(6):1466-71. doi: 10.1016/j.bmcl.2014.02.011. Epub 2014 Feb 15.

PMID:
24582987
5.

Efficacious intermittent dosing of a novel JAK2 inhibitor in mouse models of polycythemia vera.

Kraus M, Wang Y, Aleksandrowicz D, Bachman E, Szewczak AA, Walker D, Xu L, Bouthillette M, Childers KM, Dolinski B, Haidle AM, Kopinja J, Lee L, Lim J, Little KD, Ma Y, Mathur A, Mo JR, O'Hare E, Otte RD, Taoka BM, Wang W, Yin H, Zabierek AA, Zhang W, Zhao S, Zhu J, Young JR, Marshall CG.

PLoS One. 2012;7(5):e37207. doi: 10.1371/journal.pone.0037207. Epub 2012 May 18.

6.

Discovery of 1-amino-5H-pyrido[4,3-b]indol-4-carboxamide inhibitors of Janus kinase 2 (JAK2) for the treatment of myeloproliferative disorders.

Lim J, Taoka B, Otte RD, Spencer K, Dinsmore CJ, Altman MD, Chan G, Rosenstein C, Sharma S, Su HP, Szewczak AA, Xu L, Yin H, Zugay-Murphy J, Marshall CG, Young JR.

J Med Chem. 2011 Oct 27;54(20):7334-49. doi: 10.1021/jm200909u. Epub 2011 Sep 26.

PMID:
21942426
8.

Discovery of a 5H-benzo[4,5]cyclohepta[1,2-b]pyridin-5-one (MK-2461) inhibitor of c-Met kinase for the treatment of cancer.

Katz JD, Jewell JP, Guerin DJ, Lim J, Dinsmore CJ, Deshmukh SV, Pan BS, Marshall CG, Lu W, Altman MD, Dahlberg WK, Davis L, Falcone D, Gabarda AE, Hang G, Hatch H, Holmes R, Kunii K, Lumb KJ, Lutterbach B, Mathvink R, Nazef N, Patel SB, Qu X, Reilly JF, Rickert KW, Rosenstein C, Soisson SM, Spencer KB, Szewczak AA, Walker D, Wang W, Young J, Zeng Q.

J Med Chem. 2011 Jun 23;54(12):4092-108. doi: 10.1021/jm200112k. Epub 2011 May 24.

PMID:
21608528
9.

The discovery of tricyclic pyridone JAK2 inhibitors. Part 1: hit to lead.

Siu T, Kozina ES, Jung J, Rosenstein C, Mathur A, Altman MD, Chan G, Xu L, Bachman E, Mo JR, Bouthillette M, Rush T, Dinsmore CJ, Marshall CG, Young JR.

Bioorg Med Chem Lett. 2010 Dec 15;20(24):7421-5. doi: 10.1016/j.bmcl.2010.10.031. Epub 2010 Oct 12.

PMID:
21044843
10.

Real-time bioluminescence imaging of polycythemia vera development in mice.

Ma Y, Zhao S, Zhu J, Bettano KA, Qu X, Marshall CG, Young JR, Kohl NE, Scott ML, Zhang W, Wang Y.

Biochim Biophys Acta. 2009 Nov;1792(11):1073-9. doi: 10.1016/j.bbadis.2009.08.011. Epub 2009 Aug 26.

11.

Characterization of inhibitor binding to human kinesin spindle protein by site-directed mutagenesis.

Marshall CG, Torrent M, Williams O, Hamilton KA, Buser CA.

Arch Biochem Biophys. 2009 Apr 1;484(1):1-7. doi: 10.1016/j.abb.2009.01.015. Epub 2009 Jan 23.

PMID:
19467625
12.

RNA interference-mediated silencing of mitotic kinesin KIF14 disrupts cell cycle progression and induces cytokinesis failure.

Carleton M, Mao M, Biery M, Warrener P, Kim S, Buser C, Marshall CG, Fernandes C, Annis J, Linsley PS.

Mol Cell Biol. 2006 May;26(10):3853-63.

13.

Empiric antibiotic prophylaxis for patients with tick bites.

Marshall CG.

Am Fam Physician. 2006 Mar 1;73(5):774; author reply 774, 776. No abstract available.

14.

Carrier protein recognition in siderophore-producing nonribosomal peptide synthetases.

Marshall CG, Burkart MD, Meray RK, Walsh CT.

Biochemistry. 2002 Jul 2;41(26):8429-37.

PMID:
12081492
15.

Assembling the glycopeptide antibiotic scaffold: The biosynthesis of A47934 from Streptomyces toyocaensis NRRL15009.

Pootoolal J, Thomas MG, Marshall CG, Neu JM, Hubbard BK, Walsh CT, Wright GD.

Proc Natl Acad Sci U S A. 2002 Jun 25;99(13):8962-7. Epub 2002 Jun 11.

16.

The structure of VibH represents nonribosomal peptide synthetase condensation, cyclization and epimerization domains.

Keating TA, Marshall CG, Walsh CT, Keating AE.

Nat Struct Biol. 2002 Jul;9(7):522-6.

PMID:
12055621
17.

Chain termination steps in nonribosomal peptide synthetase assembly lines: directed acyl-S-enzyme breakdown in antibiotic and siderophore biosynthesis.

Keating TA, Ehmann DE, Kohli RM, Marshall CG, Trauger JW, Walsh CT.

Chembiochem. 2001 Feb 2;2(2):99-107. No abstract available.

PMID:
11828432
18.

Catalytic mapping of the vibriobactin biosynthetic enzyme VibF.

Marshall CG, Hillson NJ, Walsh CT.

Biochemistry. 2002 Jan 8;41(1):244-50.

PMID:
11772022
19.

Tailoring enzymes that modify nonribosomal peptides during and after chain elongation on NRPS assembly lines.

Walsh CT, Chen H, Keating TA, Hubbard BK, Losey HC, Luo L, Marshall CG, Miller DA, Patel HM.

Curr Opin Chem Biol. 2001 Oct;5(5):525-34. Review.

PMID:
11578925
20.

Heterocycle formation in vibriobactin biosynthesis: alternative substrate utilization and identification of a condensed intermediate.

Marshall CG, Burkart MD, Keating TA, Walsh CT.

Biochemistry. 2001 Sep 4;40(35):10655-63.

PMID:
11524010
21.

Reconstitution and characterization of the Vibrio cholerae vibriobactin synthetase from VibB, VibE, VibF, and VibH.

Keating TA, Marshall CG, Walsh CT.

Biochemistry. 2000 Dec 19;39(50):15522-30.

PMID:
11112538
22.
23.
25.

Glycopeptide antibiotic resistance genes in glycopeptide-producing organisms.

Marshall CG, Lessard IA, Park I, Wright GD.

Antimicrob Agents Chemother. 1998 Sep;42(9):2215-20.

27.
28.

Activation of ion channels in the frog endplate by several analogues of acetylcholine.

Marshall CG, Ogden D, Colquhoun D.

J Physiol. 1991 Feb;433:73-93.

29.

The actions of suxamethonium (succinyldicholine) as an agonist and channel blocker at the nicotinic receptor of frog muscle.

Marshall CG, Ogden DC, Colquhoun D.

J Physiol. 1990 Sep;428:155-74. Erratum in: J Physiol (Lond) 1991 Apr;435:645-6.

30.

Function of nicotinic synapses.

Colquhoun D, Cachelin AB, Marshall CG, Mathie A, Ogden DC.

Prog Brain Res. 1990;84:43-50. Review. No abstract available.

PMID:
2267314
31.

Voltage-activated membrane currents in rat cerebellar granule neurones.

Cull-Candy SG, Marshall CG, Ogden D.

J Physiol. 1989 Jul;414:179-99.

33.

Calcium-dependent action potentials in leech giant salivary cells.

Marshall CG, Lent CM.

J Exp Biol. 1984 Nov;113:367-80.

34.

FOSSIL MICROORGANISMS: POSSIBLE PRESENCE IN PRECAMBRIAN SHIELD OF WESTERN AUSTRALIA.

MARSHALL CG, MAY JW, PERRET CJ.

Science. 1964 Apr 17;144(3616):290-2.

PMID:
14169713
35.

Alkyl-Dimethyl-Benzyl-Ammonium-Chloride for Sanitization of Eating and Drinking Utensils.

Krog AJ, Marshall CG.

Am J Public Health Nations Health. 1940 Apr;30(4):341-8. No abstract available.

Supplemental Content

Loading ...
Support Center